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RAPID COMMUNICATION
A nonsense mutation in the COL4A5 collagen gene in a family
with X-linked juvenile Alport syndrome
JENS MICHAEL HERTZ, NuNA HEIscrn, JING ZHOU, UFFE BIRK JENSEN, and KARL TRYGGVASON
Institute of Human Genetics, University of Aarhus, Aarhus C., Denmark; Biocenter Oulu and Department of Biochemistty, University of Oulu, Oulu,
Finland; and Bringham and Women Hospital, Renal Division, Boston, Massachusetts, USA
A nonsense mutation in the COL4A5 collagen gene in a family with
X-linked juvenile Alport syndrome. The X-linked form of Alport syn-
drome is associated with mutations in the COL4A5 gene encoding the
a5-chain of type IV collagen. By using PCR-amplification and direct
sequencing we identified a novel mutation involving a deletion of the last
two bases in the codon GGA for Glycine-1479 in exon 47 of the COL4A5
gene in a patient with a juvenile form of X-linked Alport syndrome with
deafness. This two base deletion caused a shift in the reading frame and
introduced a premature stop codon which resulted in an a5(IV)-chain
shortened by 202 residues and lacking almost the entire NC1 domain. The
mutation was found to co-segregate with the disease in the family. The
information of the sequence variation in this family was used to perform
carrier detection and prenatal diagnosis by allele-specific oligonucleotide
hybridization analysis and direct sequencing of PCR amplified exon 47.
Prenatal diagnosis on chorionic villi tissue, obtained from one of the
female carriers in the family, revealed a male fetus hemizygous for the
mutated allele. A subsequent prenatal test in her next pregnancy revealed
a normal male fetus. Prenatal diagnosis of Alport syndrome has not
previously been reported.
Alport syndrome (AS) is a hereditary glomerular kidney disease
characterized by hematuria and progressive renal failure and
often associated with high-tone sensorineural deafness, anterior
lenticonus and macular flecks. The disease is clinically as well as
genetically heterogenous, and a classification based on the age at
end-stage renal disease (ESRD), the occurrence of extrarenal
manifestations and the inheritance, has been suggested [1]. In the
juvenile form of AS, ESRD occurs before age 30.
The inheritance of AS is X-linked dominant in the majority of
kindreds [2—4], and a locus at Xq22 has been identified by linkage
to different X-chromosomal RFLP markers [5—71. Ultrastructural
changes [8, 91 and immunohistochemical findings [10, 11] sug-
gested AS to be a type IV collagen disorder, and the gene for the
cs5-chain of type IV collagen (COL4A5) was cloned and assigned
to the AS locus at Xq22 [12]. Several different DNA rearrange-
ments and point mutations have now been identified in this gene
in patients with AS [13—20].
Another type IV collagen gene (COL4A6) encoding the
a6(IV)-chain, has recently been identified and shown to be
located head-to-head and within 452 base pairs of the COL4A5
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gene on the X-chromosome at Xq22 [21]. No single mutations
have so far been identified in this gene, but deletions disrupting
both COL4A5 as well as COL4A6 have been identified in patients
with AS and diffuse leiomyomatosis [211. In an ongoing study
aiming at the search for mutations in the COL4A5 gene in 40
Danish Alport families, we have so far identified three different
point mutations [22—24].
In this report we describe a novel mutation in exon 47 of the
COL4A5 gene in a large Danish kindred segregating for an
X-linked form of juvenile Alport syndrome with deafness. Iden-
tification of the mutation in the proband in this family made
carrier detection as well as prenatal diagnosis possible in other
members of the family. We have analyzed two separate first
trimester chorionic villi biopsies, obtained from one of the female
carriers in the family, for the presence of the mutation. Prenatal
diagnosis of AS has not previously been reported.
Methods
Family history
A pedigree of the Danish Alport kindred A9 is shown in Figure
1. The proband (111-9) is a 30-year-old male with a juvenile form
of Alport syndrome with deafness. He had suffered from protein-
uria and hematuria since early childhood. A sensorineural hearing
loss was first detected at the age of 7, but no ophthalmological
manifestations of the disease have been recognized. A kidney
biopsy has never been performed. The renal disease progressed
steadily and at the age of 20 he reached terminal uremia. Renal
transplantation with a kidney from an unrelated donor was
performed when he was 22-years-old, but the graft was rejected
five years later. He was re-transplanted at 29-years-old and this
kidney is still functioning. An older brother, not shown in the
pedigree, died of terminal uremia at the age of 16 years. He had
also deafness, but no lenticonus. A male cousin (111-5) has been
transplanted because of chronic renal failure and he has also
sensorineural deafness. The maternal grandmother (1-2) had a
slightly elevated serum creatinine (180 imol/liter) at age of 89.
The disease could not be traced further back in the family. The
proband's mother (11-7) and three sisters (111-7, 111-il and 111-12)
have microscopic hematuria and proteinuria, but serum creatinine
within the normal range. A younger brother (111-13) is healthy. No
hematuria or proteinuria could be detected in a single urine
sample from the mother's sister (11-4), and a serum creatinine was
normal. The mother's three brothers (11-2, 11-3 and 11-6) and two
sisters (11-1 and 11-9) are all healthy, and without hematuria and
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Fig. 1. A. Pedigree of Alport kindredA9. Symbols are: (0) normal female, (0) normal male, (•) affected male, and (®) carrier female. B. Allele specific
oligonucleotide hybridization (dot-blot analysis) of PCR-amplified exon 47 from the COL4A5 gene for carrier detection. Duplicate filters were
hybridized with 32P radiolabeled oligonucleotides corresponding to either the normal sequence (N) or the mutant sequence (M). DNA from the
hemizygous proband (111-9) and his male cousin (111-5) are positive with the mutant oligonucleotide probe (M) and negative with the normal
oligonucleotide probe (N). The heterozygous females (1-2, 11-4, 11-7, 111-7, Ill-il, and 111-12) are positive with both oligonucleotide probes, whereas the
healthy females (11-1 and 11-9) are positive only for the normal oligonucleotide probe.
proteinuria, and had normal serum creatinine. The pedigree is
compatible with X-linked inheritance.
The proband's sister (111-11) was referred for prenatal diagnosis
of Alport syndrome for the first time at 26-years-old while in her
second pregnancy. Her first child was a healthy daughter. A
chorionic villi biopsy was obtained by the transabdominal route in
the 10th week of pregnancy without complications, and direct
chromosome analysis after 24 hour incubation of the chorionic
tissue revealed a normal male kaiyotype: 46,XY. The rest of the
tissue was used for the DNA test (Fig. 2). Due to the result of the
prenatal test, she decided on termination of the pregnancy, which
was performed 6 days after the biopsy was obtained, and without
complications. The second prenatal test on chorionic villi tissue
from 111-11 was performed 17 months later in the 11th week of her
third pregnancy. Chromosome analysis after 24 hour incubation of
the tissue revealed a normal male karyotype: 46,XY, and the rest
of the tissue was used for DNA preparation for prenatal diagnosis
of AS.
DNA preparation
Genomic DNA was extracted from peripheral blood lympho-
cytes according to standard protocols. DNA was prepared from
chorionic villi, after washing the tissue twice in PBS free of Ca2
and Mg2, by incubation at 56°C for 90 minutes in a buffer at pH
10.5 containing 10 mrvs Tris, 1 mM EDTA, 150 mrvi NaCI, 0.5%
SDS, and 100 .tg/m1 proteinase K. The DNA was then extracted
using an equal volume of phenol and chioroform-isoamylalcohol
(25:24:1), followed by an equal volume of chloroform-isoamylal-
cohol (24:1). The upper aqueous phase was precipitated with one
tenth volume of 3 M sodium acetate at pH 5.2 and alcohol, and the
Fig. 2. Prenatal diagnosis ofAlport syndrome. A. Partial pedigree of Alport
kindred A9. The symbols used are as described in the legend to Fig. 1. NC
= normal control. B. Allele-specific oligonucleotide hybridization (dot-
blot analysis) of PCR-amplified exon 47 from the COL4A5 gene for
prenatal diagnosis of Alport syndrome in 111-11. DNA from a chorionic
villus biopsy (IV-6) is positive only for the mutant allele (M), indicating
that the male fetus was affected, whereas DNA from a chorionic villus
sample in her next pregnancy (IV-7) was positive only for the normal allele
(N), therefore indicating a healthy male fetus.
DNA redissolved in TE buffer and treated with RNase (50 .rg/ml)
at 37°C for one hour.
Southern blotting analysis
Two different techniques were used in order to identify the
mutation in the present case: (a) Southern blotting analysis for
NC
A 0
6 7
• •.M•
Hertz et al. Prenatal Diagnosis of A/port syndrome 329
major structural gene rearrangements, and (b) PCR-amplification
and direct sequencing of the different exons.
DNA from the proband (111-9) was digested with seven differ-
ent restriction enzymes and hybridized to seven cDNA inserts:
JZ4, HT14.1, HT14.2, HT14.3, PL31, MD6 and PC4, spanning the
entire COL4A5 gene [23] using standard protocols.
Polymerase chain reaction and solid phase sequencing
Exon 47 was PCR amplified using a pair of primers, including
biotinylated primer B*5E47A: 5 '-ATGAGGTCATAATG'1T11'-
GTC containing sequences from intron 46, and primer 5E47B:
5'-CACTTTGGCCAGGCTACTC from intron 47 [Heiskari et al,
manuscript in preparation]. Primer B*5E47A was biotinylated
during the oligonucleotide synthesis with biotin amidite Biodite
(Pharmacia). The polymerase chain reaction was carried out in a
reaction volume of 50 sl with 100 ng of genomic DNA, 5 pmol
primers, 1.5 mM MgC12, 200 M nucleotides and 1 U of Dy-
naZyme DNA polymerase (Finnzymes, Finland). The samples
were first denatureted at 95°C for five minutes followed by 40
cycles of 95°C for 30 seconds, annealing of primers at 50°C for one
minute and extension at 72°C for one minute in a Biometra
TRIO-Thermoblock.
For DNA sequencing Streptavidin-coated magnetic beads
(Dynabeads M-280 Streptavidin, Dynal, Norway) were used to
bind covalenty the biotin-labeled and PCR-amplified double-
stranded DNA fragments to a solid phase. The non-biotinylated
DNA strand was melted away by 0.1 M NaOH and the specific
fluorescin-labeled nested sequencing primer F*5E47B:
GGATTFCTGAAACA, containing sequence from intron 47, was
annealed to the immobilized single-stranded template. The se-
quencing primer F*5E47B was 5'-end labeled with fluorescein
amidite FluorePrime (Pharmacia) during oligonucleotide synthe-
sis. Sequencing was subsequently carried out using the AutoRead
Sequencing Kit (Pharmacia), and an Automated Laser Fluores-
ence DNA Sequencer (Pharmacia, LKB) was used for sequencing
analysis.
Allele specific oligonucleotide hybridization
PCR-amplification of exon 47 followed by allele specific oligo-
nucleotide hybridization was carried out to show the presence or
absence of the mutation among the family members, a normal
control as well as for the prenatal test.
Exon 47 [25] was amplified for the allele specific oligonucleo-
tide hybridization by using the flanking 24-mer oligonucleotides
E47F: 5'-TCTFGTATACTGA'fl7ATVFCGTGG-3' and E47R:
5 '-CAGTAGGAAA1TAGATATFGATFA-3'. The polymerase
chain reaction was carried out in a reaction volume of 25 .d with
100 ng genomic template DNA, 1.5 mivi MgC12, and 200 LM
nucleotides. After an initial denaturation at 96°C for 10 minutes,
1 U Taq DNA polymerase (Boehringer Mannheim) was added,
followed by 30 cycles of 92°C denaturation for 50 seconds,
annealing of the primers at 50°C for 50 seconds, and extension at
72°C for one minute and 30 seconds in a Hybaid Thermal Cycler.
Duplicate filters were made by loading a dot-blot apparatus
(MINIFOLD) with 5 sl of the PCR product from each person
onto two parallel slots containing nitrocellulose filters. Each filters
were hybridized overnight at 42°C in 5 X SSPE, 10 )< Denhardt's
and 0.1% SDS with either the normal 18-mer oligonucleotide
probe N: 5'-CCACAGGGAACACTFCAG-3' or the mutant oh-
gonucleotide probe M: 5'-CCACAGGACACTTCAGGT-3', syn-
thezied according to the sequence data of Zhou et al [26] and
end-labeled with 32P CTP by Terminal Transferase (Boehringer
Mannheim). Washing was performed once with the hybridization
buffer at room temperature for 10 minutes, followed by 2.5 x
SSPE and 0.1% SDS at 47°C for 50 minutes and in the same buffer
at 52°C for 30 minutes. The filters were then autoradiographed at
room temperature for one hour.
Sequencing of PCR-amplified DNA from the chorionic villi
biopsies
The results of the prenatal tests by allele specific hybridization
analysis were verified by direct sequencing of DNA from the
chorionic villi biopsies (IV-6 and IV-7) together with DNA from
the proband (111-9) and an unrelated healthy male control as
positive and negative controls, respectively. The direct sequencing
was performed on single-stranded template DNA from exon 47
using the CircumVent Thermal Cycle Sequencing Kit (New
England Biolabs). Single-stranded template DNA was prepared
by asymmetric PCR using unequal contrations of the primers for
amplification with a ratio of 100:1 and 45 cycles instead of 30. All
other PCR conditions were the same as for the PCR amplification
for allele-specific oligonucleotide hybridization.
Results
Detection of the mutation
The Southern blotting analysis of genomic DNA digested with
PstI, EcoRI, TaqI, MspI, XmnI, BamHI, and Hindu!, did not
reveal any major DNA rearrangements in the COL4A5 gene in
the proband (data not shown).
Since the Southern blotting analysis was unsuccessful in iden-
tifying the mutation in this family, an approach of systematic
PCR-amplification and direct sequencing of exons was initiated.
This analysis revealed a sequence variation in exon 47 [25] in the
DNA of the affected male proband (111-9) (Fig. 3). Exon 47 is a
junction exon encoding the carboxyl-terminal end of the collage-
nous domain and a part of the non-collagenous (NC1) domain
[25]. The mutation in exon 47 in the present case involved the
deletion of the last two bases of the GGA codon for Glycine-1479.
This mutation alters the reading frame and changes five residues
before the introduction of a premature TGA stop codon. This
results in an a5(IV)-chain shortened by 202 residues, lacking
almost the entire NC1 domain. The NC1 domain of the a5(IV)-
chain is cysteine-rich and plays an important role in the assembly
of the three a-chains in type IV collagen by forming intra- and
intermolecular disulphide bridges, and also by cross linking adja-
cent triple-helical molecules, forming the network structure of
type IV collagen in the glomerular basement membrane [27].
This two-base deletion in exon 47 in Alport kindred A9
apparently causes a juvenile form of AS with deafness, since all
three affected male members of the family developed ESRD
before the age of 20 years and have sensorineural deafness.
Renieri et al [15] describe three small frameshift deletions in
three Alport kindreds. These frameshift mutations in exon 39, 41
and 50, results in loss of the entire NC1 domain or part of it, and,
as in the present case, causes a juvenile form of the disease with
deafness. Four other frameshift mutations due to small deletions:
an 8 bp deletion in exon 51 causing a premature chain termination
of the NC1 domain [14], a 7 bp deletion and change in three
nucleotides in exon 42 [17], and single base pair deletions in exon
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Normal male.
Glyl 479 (GGA)
Proband 111-9.
Deletion of the two last bases
in the codon GGA for Glyl 479
Fig. 3. Two-base deletion mutation in the COL4A5 gene in Danish kindred A9. Comparison of sequences from a normal male (A), and the affected
proband 111-9 (B). The bases of the GGA codon for Glycine-1479 in the normal allele are indicated by arrows in A. In the proband only one base (G)
remains of the Glycine-1479 codon (B; arrow).
39 and 42 [181, also results in juvenile AS with deafness. The
mutation in exon 47 identified in this study has not previously
been described, and it is the first mutation to be reported for this
exon. Since the mutation co-segregates with the Alport phenotype
in this family, it is likely to cause the disease. This is supported by
the presently extensive body of data demonstrating the association
of mutations in the COL4A5 gene and AS [13]. Presently, over 40
mutations have been reported in the COL4A5 gene, and almost all
of them are being unique for the different kindreds, with only few
exceptions. Three unrelated individuals, one from a Danish
family, one from a family from Utah, and one from a family from
The Netherlands, seem to carry the same single base substitution
(G — A) in the codon for Arginine-1563 in exon 48 [24, 281.
The knowledge about the mutation in this family allowed for
diagnosis of the disease in the males and for carrier detection in
the females by PCR amplification and direct sequencing in all 17
members of the family. The analysis revealed that the proband
(111-9) and his male cousin (111-5) both are hemizygous for the
mutated allele, and that the females 1-2, 11-4, 11-7, 111-7, Ill-li,
and 111-12 all are heterozygous with one normal allele and one
mutated allele. The absence of hematuria and proteinuria in 11-4,
despite that she is obligate carrier of the disease and sequencing
demonstrated her to carry the mutated allele, could be explained
by incomplete penetrance in female carriers of AS [291. However,
only a single urine sample from 11-4 has been available for
analysis. No other members of the family, from which we have
obtained DNA, was found to carry the mutated allele. The
distribution of mutated and normal alleles was also analyzed by
allele specific oligonucleotide hybridization, and, as expected, this
yielded identical results (Fig. 1).
Discussion
Prenatal diagnosis of the disease
Shortly after the identification of this mutation, one of the
females in the family, the probands sister (111-11) became preg-
nant and was referred for first trimester prenatal diagnosis of AS.
She has clinical signs of the disease in form of persistent micro-
scopic hematuria and proteinuria, but her hearing is normal. PCR
amplification and direct sequencing, as well as allele-specific
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oligonucleotide hybridization analysis revealed that she in fact is
carrier of the mutation (Fig. 1). A prenatal test was performed in
the 10th week of pregnancy on chorionic villi tissue. Chromosome
analysis revealed a normal male karyotype 46,XY, and subsequent
DNA analysis by allele-specific oligonucleotide hybridization
analysis indicated the presence of the mutated allele in the fetus
(IV-6) (Fig. 2), consistent with the development of AS. PCR
amplification and direct sequencing of exon 47 verified the
existence of the two-base deletion in the fetus. Due to the result
of the prenatal test, the mother decided on termination of the
pregnancy. Analysis of a second chorionic villus sample 17 months
later also revealed a male fetus, but this time with the normal
allele and therefore healthy (Fig. 2).
This is the first report on prenatal diagnosis of Alport syn-
drome. Carrier detection and prenatal diagnosis of the X-linked
form of Alport syndrome can be performed by specific mutation
analysis in families with a well characterized mutation, as de-
scribed in the present report. However, in those families in which
the mutation as yet has not been identified, but where X-linked
inheritance has been verified by linkage analysis, closely linked
polymorphic markers, such as the (CA)-dinucleotide-repeat-
polymorphisms, identified in one of the genomic clones from the
COL4A5 gene [30], can be used for diagnosis. Prenatal diagnosis
of another, and frequent cause of end-stage renal disease, auto-
somal dominant polycystic kidney disease (ADPKD1), has previ-
ously been reported [31]. The gene for ADPKD1 maps to the
short arm of chromosome 16 [32], whereas the gene itself not yet
has been identified. Presymptomatic as well as prenatal diagnosis
of ADPKD1 can, therefore, thus far only be performed by using
closely linked polymorphic markers, in order to determine which
alleles are segregating with the gene in the family, and only in
families with at least two affected members.
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